Trial Profile
Phase II trial of MK 5172 in combination with daclatasvir in patients with chronic hepatitis C
Status:
Planning
Phase of Trial:
Phase II
Latest Information Update: 30 Apr 2013
Price :
$35
*
At a glance
- Drugs Daclatasvir (Primary) ; Grazoprevir (Primary)
- Indications Hepatitis C
- Focus Therapeutic Use
- Sponsors Merck & Co
- 30 Apr 2013 New trial record